TPT1 Antibody

What is TPT1 and what cellular functions does it regulate?

TPT1 (tumor protein, translationally-controlled 1), also known as TCTP, is a highly expressed protein in tumor cells that participates in various cellular activities including protein synthesis, growth, and cell survival. Research has identified TPT1 as a direct target of the tumor suppressor TP53/p53 . Recent studies have demonstrated that TPT1 plays a significant role in the regulation of autophagy via the MTORC1 pathway and AMPK pathways . TPT1 acts as a negative regulator of autophagy by activating MTORC1 and deactivating AMPK, influencing the BECN1 interactome by affecting BCL2 expression levels, thereby regulating autophagosome formation .

What applications can TPT1 antibody be used for in research?

Based on validated research applications, TPT1 antibody can be used for multiple experimental techniques including:

The 10824-1-AP TPT1 antibody has been positively validated for Western blot in A431 cells, mouse placenta tissue, and MCF-7 cells; for IP in human placenta tissue; for IHC in human colon cancer tissue; and for IF/ICC in HeLa cells .

What are the recommended experimental conditions for using TPT1 antibody?

For optimal experimental results with TPT1 antibody, the following dilutions are recommended:

For IHC applications, antigen retrieval with TE buffer pH 9.0 is suggested, although citrate buffer pH 6.0 may be used as an alternative . It is recommended to titrate the antibody in each testing system to obtain optimal results, as the required dilution can be sample-dependent .

What is the molecular weight of TPT1 and how does it appear on Western blots?

TPT1 has a calculated molecular weight of 22 kDa, though the observed molecular weight in Western blots typically ranges from 22-25 kDa . This slight discrepancy between calculated and observed molecular weights may be due to post-translational modifications or the presence of protein isoforms. When using TPT1 antibody, researchers should expect to see bands in this molecular weight range when performing Western blot analysis .

How can I validate TPT1 antibody specificity in my experimental system?

Validating antibody specificity is crucial for ensuring reliable experimental results. For TPT1 antibody, implement these validation strategies:

• Genetic approach: Use TPT1 knockdown (shRNA, siRNA) or knockout (CRISPR-Cas9) models to confirm the absence or reduction of the antibody signal. Research has demonstrated that TPT1 knockdown leads to a reduction in TPT1 signal in Western blot experiments .

• Multiple antibody validation: Use antibodies from different vendors or antibodies targeting different epitopes of TPT1 to confirm consistent patterns.

• Positive control tissues/cells: Include samples known to express TPT1, such as A431 cells, MCF-7 cells, or mouse placenta tissue, which have been validated to show positive WB signals with TPT1 antibody .

• Immunoprecipitation followed by mass spectrometry: This approach can confirm that the antibody is specifically pulling down TPT1 and not cross-reacting with other proteins.

• Recombinant protein control: Use purified TPT1 protein as a positive control to confirm antibody binding.

What are the mechanisms by which TPT1 regulates autophagy and how can TPT1 antibody be used to study this process?

TPT1 regulates autophagy through multiple mechanisms:

• MTORC1 pathway: TPT1 activates the MTORC1 pathway, which is a major negative regulator of autophagy. TPT1 knockdown leads to inhibition of MTORC1 and subsequent induction of autophagy .

• AMPK pathway: TPT1 deactivates the AMPK pathway. When TPT1 is depleted, AMPK is activated, which promotes autophagy .

• BECN1 interactome modification: TPT1 affects the BECN1 (Beclin 1) interactome by regulating BCL2 expression. Knockdown of TPT1 reduces BCL2 expression, which decreases the interaction between BECN1 and BCL2, enhancing BECN1-phosphatidylinositol 3-kinase (PtdIns3K)-UVRAG complex formation, leading to autophagosome formation .

• Autophagosome maturation: TPT1 depletion promotes not only autophagosome formation but also autophagosome maturation .

TPT1 antibody can be used to study these processes through Western blot analysis, co-immunoprecipitation, immunofluorescence, and tissue analysis techniques to correlate TPT1 expression with autophagy markers and protein interactions.

How does TPT1 expression correlate with autophagy in vivo and how can this be assessed using TPT1 antibody?

In vivo studies using Tpt1 heterozygote knockout mice have provided valuable insights into TPT1's role in regulating autophagy:

• Liver analysis: Livers of Tpt1 +/- mice display higher levels of LC3-I to LC3-II conversions, reduced SQSTM1/p62 levels, suppressed MTORC1 signaling, and activated AMPK .

• Kidney analysis: Kidneys of Tpt1 +/- mice show a tendency towards increased LC3-I to LC3-II conversion (not statistically significant, p-value = 0.1984), significantly reduced SQSTM1/p62 levels, and reduced TPT1 expression .

• Autophagic flux assessment: Leupeptin treatment in Tpt1 +/- mice livers augmented LC3-II accumulation and blocked SQSTM1/p62 degradation, demonstrating that haploinsufficient expression of TPT1 induces early steps of autophagy in vivo .

To assess TPT1's role in autophagy in vivo using TPT1 antibody, researchers can perform Western blot analysis, immunohistochemistry, co-immunostaining, and comparative analysis between wild-type and autophagy-modulated tissues.

How should I interpret conflicting data regarding TPT1's role in autophagy regulation?

Research has documented some seemingly contradictory findings regarding TPT1's role in autophagy. While most studies indicate that TPT1 negatively regulates autophagy via MTORC1 activation under normal conditions, there have been reports suggesting that TPT1 might positively regulate autophagy under hypoxic conditions .

When interpreting conflicting data:

• Consider cellular context: TPT1's effects on autophagy may be cell type-specific or dependent on cellular conditions (e.g., normoxic vs. hypoxic).

• Examine experimental conditions: Different outcomes might result from variations in experimental design, timing of measurements, or the specific aspects of autophagy being assessed.

• Assess autophagic flux: Autophagy is a dynamic process, and LC3-II levels can fluctuate during induction. Measuring autophagic flux (using inhibitors like bafilomycin A1) rather than just LC3-II levels at a single time point provides more reliable information .

• Use multiple autophagy markers: Don't rely solely on LC3-II levels; include other markers like SQSTM1/p62 degradation, BECN1 complex formation, and autolysosome formation .

What are the critical considerations for using TPT1 antibody in Western blot analysis?

To obtain optimal and reliable results when using TPT1 antibody in Western blot experiments:

• Sample preparation:

  • Use appropriate lysis buffers that preserve TPT1 protein integrity

  • Include protease inhibitors to prevent degradation

  • Determine optimal protein loading amount (typically 20-50 μg of total protein)

• Electrophoresis conditions:

  • Use 10-15% SDS-PAGE gels for optimal resolution of the 22-25 kDa TPT1 protein

  • Include molecular weight markers that clearly mark the 20-25 kDa range

• Transfer conditions:

  • Use PVDF or nitrocellulose membranes

  • Optimize transfer time and voltage for proteins in the 20-25 kDa range

• Antibody incubation:

  • Start with a 1:1000 dilution and optimize as needed (range: 1:1000-1:8000)

  • Incubate at 4°C overnight for optimal results

  • Use appropriate blocking solution (5% non-fat milk or BSA in TBST)

• Controls:

  • Include positive controls (A431 cells, MCF-7 cells, or mouse placenta tissue)

  • Include negative controls (TPT1 knockdown samples if available)

  • Consider using beta-actin or GAPDH as loading controls

What approaches can be used to study TPT1's role in the BECN1 interactome using TPT1 antibody?

To investigate TPT1's influence on the BECN1 interactome:

• Co-immunoprecipitation (Co-IP):

  • Immunoprecipitate with TPT1 antibody and blot for BECN1 and its interacting partners (BCL2, PtdIns3K, UVRAG)

  • Alternatively, immunoprecipitate with BECN1 antibody and blot for TPT1

  • Compare Co-IP results between control and TPT1-depleted cells

Research has shown that TPT1 knockdown reduces BCL2 expression, decreases the interaction between BECN1 and BCL2, and enhances BECN1-PtdIns3K-UVRAG complex formation .

• Proximity ligation assay (PLA):

  • Use TPT1 antibody together with antibodies against BECN1 or its interacting partners

  • Visualize and quantify protein-protein interactions in situ

• Immunofluorescence co-localization:

  • Perform double immunofluorescence staining with TPT1 antibody and antibodies against BECN1 complex components

  • Analyze co-localization using confocal microscopy

How can I optimize TPT1 antibody for immunohistochemistry (IHC) applications?

For successful IHC applications with TPT1 antibody:

• Tissue preparation:

  • Fix tissues with 10% neutral buffered formalin or 4% paraformaldehyde

  • Ensure proper tissue processing and paraffin embedding

  • Use freshly cut sections (4-6 μm thick) for optimal antigen detection

• Antigen retrieval:

  • Use TE buffer pH 9.0 as the primary recommended method

  • Alternatively, citrate buffer pH 6.0 can be used

  • Optimize retrieval time and temperature (typically 95-100°C for 15-20 minutes)

• Antibody dilution and incubation:

  • Start with 1:1000 dilution and titrate if needed (range: 1:1000-1:4000)

  • Incubate at 4°C overnight or at room temperature for 1-2 hours

  • Use appropriate diluent (usually 1% BSA in PBS)

• Controls:

  • Include positive control tissues (human colon cancer tissue has been validated)

  • Include negative controls (omit primary antibody or use isotype control)

  • Consider using TPT1 knockdown or knockout tissues if available

What methods can be used to study TPT1's involvement in autophagy using TPT1 antibody?

To investigate TPT1's role in autophagy:

• Western blot analysis:

  • Detect changes in TPT1 expression along with autophagy markers (LC3-II, SQSTM1/p62)

  • Examine phosphorylation status of MTORC1 and AMPK targets

  • Compare results between control and autophagy-modulated conditions (starvation, rapamycin treatment)

• Immunofluorescence:

  • Use TPT1 antibody alongside fluorescent markers for autophagosomes (LC3) and lysosomes (LAMP1)

  • Apply the mRFP-GFP-LC3 tandem fluorescent method to assess autophagic flux

  • Analyze co-localization patterns and quantify autophagosome/autolysosome numbers

• Tissue analysis:

  • Compare TPT1 expression and autophagy markers in tissues from wild-type and autophagy-modulated models

  • Use leupeptin assays to assess autophagic flux in vivo

Experimental data has shown that TPT1 knockdown enhances GFP-LC3 puncta formation, increases LC3-II levels, promotes SQSTM1/p62 degradation, increases both autophagosome and autolysosome formation, and enhances colocalization of RFP-LC3 with GFP-LAMP1 .

Why might I be seeing multiple bands or unexpected band sizes when using TPT1 antibody in Western blot?

Multiple bands or unexpected band sizes could result from several factors:

• Post-translational modifications: TPT1 may undergo modifications like phosphorylation or ubiquitination, resulting in shifts in apparent molecular weight.

• Protein degradation: Incomplete protease inhibition during sample preparation may lead to TPT1 degradation products appearing as lower molecular weight bands.

• Isoforms or splice variants: TPT1 may have isoforms or splice variants in different tissues or cell types, resulting in bands of varying sizes.

• Cross-reactivity: The antibody might cross-react with structurally similar proteins, especially at higher concentrations.

To address these issues, optimize sample preparation with fresh protease inhibitors, titrate the antibody concentration (try more dilute solutions), increase washing steps duration and frequency, and compare results with TPT1 knockdown samples.

How can I improve signal-to-noise ratio when using TPT1 antibody in immunofluorescence?

To improve signal-to-noise ratio in immunofluorescence experiments:

• Fixation optimization:

  • Test different fixatives (4% PFA, methanol, or acetone)

  • Optimize fixation time (typically 10-20 minutes at room temperature)

• Permeabilization:

  • Test different permeabilization agents (0.1-0.5% Triton X-100, 0.1% Saponin)

  • Optimize permeabilization time (typically 5-15 minutes)

• Blocking:

  • Use sufficient blocking time (1 hour minimum)

  • Try different blocking agents (5-10% normal serum, 3-5% BSA)

  • Consider adding 0.1-0.3% Triton X-100 to blocking solution

• Antibody dilution:

  • Start with 1:200 dilution and titrate as needed (range: 1:200-1:800)

  • Incubate at 4°C overnight for optimal results

Positive IF/ICC signals have been validated in HeLa cells, making them a good positive control for optimizing protocols .

How can TPT1 antibody be used to investigate the therapeutic potential of targeting TPT1 in diseases associated with autophagy dysfunction?

TPT1 antibody can facilitate research into TPT1's therapeutic potential through:

• Disease model analysis:

  • Compare TPT1 expression between normal and diseased tissues

  • Correlate TPT1 levels with autophagy markers in disease samples

  • Assess whether TPT1 modulation normalizes autophagy in disease models

• Drug discovery applications:

  • Screen compounds that modulate TPT1 expression or function

  • Use TPT1 antibody to monitor drug effects on TPT1 and autophagy

  • Investigate combination therapies targeting TPT1 and other autophagy regulators

• Mechanism-based therapeutic approaches:

  • Target specific interactions between TPT1 and autophagy regulators

  • Focus on TPT1's effects on MTORC1, AMPK, or BECN1 interactome

  • Develop strategies to modulate TPT1 in a tissue-specific manner

Since TPT1 negatively regulates autophagy, its inhibition could potentially enhance autophagy in conditions where autophagy dysfunction contributes to disease pathogenesis, such as neurodegenerative disorders, certain cancers, and metabolic diseases .

How might TPT1's dual role in regulating both apoptosis and autophagy be investigated using TPT1 antibody?

To investigate TPT1's dual regulatory role in apoptosis and autophagy:

• Temporal analysis:

  • Use TPT1 antibody to track expression levels during transitions between autophagy and apoptosis

  • Perform time-course experiments with various stressors

  • Determine whether TPT1 serves as a molecular switch between these processes

• Interactome analysis:

  • Compare TPT1 interacting partners under conditions favoring autophagy vs. apoptosis

  • Identify shared vs. process-specific interactions

  • Investigate how these interactions influence pathway choice

• Cross-talk investigation:

  • Examine how modulation of TPT1-mediated autophagy affects apoptosis sensitivity

  • Investigate whether TPT1's anti-apoptotic function depends on autophagy regulation

  • Assess the role of BCL2 as a common mediator in both processes

Since TPT1 regulates BCL2 expression, which is involved in both autophagy (through BECN1 interaction) and apoptosis (through interactions with pro-apoptotic proteins), this connection represents a key node in the cross-talk between these processes .